1. Polydatin Induces Differentiation and Radiation Sensitivity in Human Osteosarcoma Cells and Parallel Secretion through Lipid Metabolite Secretion
- Author
-
Pilar Chacon Millan, Paola Stiuso, Stefania Lama, Salvatore Cappabianca, Angelo Sangiovanni, Carlo Caputo, Michele Caraglia, Pasquale Ferranti, Amalia Luce, Annalisa Itro, Luce, Amalia, Lama, Stefania, Millan, Pilar Chacon, Itro, Annalisa, Sangiovanni, Angelo, Caputo, Carlo, Ferranti, Pasquale, Cappabianca, Salvatore, Caraglia, Michele, Stiuso, Paola, Luce, A., Lama, S., Millan, P. C., Itro, A., Sangiovanni, A., Caputo, C., Ferranti, P., Cappabianca, S., Caraglia, M., and Stiuso, P.
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Aging ,Ceramide ,Glucoside ,Article Subject ,Biochemistry ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Glucosides ,Downregulation and upregulation ,Stilbenes ,medicine ,Humans ,Secretion ,Osteosarcoma ,QH573-671 ,Bone cancer ,Mesenchymal stem cell ,Cell Differentiation ,Cell Biology ,General Medicine ,Lipid Metabolism ,medicine.disease ,Sphingolipid ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Cytology ,Research Article ,Drugs, Chinese Herbal ,Human - Abstract
Osteosarcoma is a bone cancer characterized by the production of osteoid tissue and immature bone from mesenchymal cells. Osteosarcoma mainly affects long bones (femur is most frequently site) and occur in children and young adults with greater incidence. Here, we investigated the role accomplished by polydatin, a natural antioxidative compound, in promoting osteogenic differentiation alone or after radiation therapy on osteosarcoma cells. In vitro, polydatin significantly induced cell cycle arrest in S-phase and enhanced bone alkaline phosphatase activity. Moreover, the differentiation process was paralleled by the activation of Wnt-β-catenin pathway. In combination with radiotherapy, the pretreatment with polydatin promoted a radiosensitizing effect on osteosarcoma cancer cells as demonstrated by the upregulation of osteogenic markers and reduced clonogenic survival of tumor cells. Additionally, we analyzed, by mass spectrometry, the secretion of sphingolipid, ceramides, and their metabolites in osteosarcoma cells treated with polydatin. Overall, our results demonstrate that polydatin, through the secretion of sphingolipids and ceramide, induced osteogenic differentiation, alone and in the presence of ionizing therapy. Future investigations are needed to validate the use of polydatin in clinical practice as a potentiating agent of radiotherapy-induced anticancer effects.
- Published
- 2021
- Full Text
- View/download PDF